The CRM Reset in Pharma: Migration, AI, and the Pursuit of Commercial Advantage
The Migration Everyone Argues About, and the Part That Decides It
The platform decision is the easy part.
Getting reps to trust it, adopt the AI, and stick with it is where transformation lives or dies.
You could build the best tool in the world, but if reps do not find value in it, it is not going to be successful. - A panelist at Axtria Ignite 2026
THE PROBLEM
The migration landed on your desk. Now you own whether it sticks.
A CRM decision you never requested is now yours to defend, and the field still must adopt it.
- You are paying a premium to stand still. Leadership asks why the subscription changed; it became unavoidable anyway.
- Adoption is the metric you cannot mandate. The committee tracks the go-live date, not whether reps change how they work.
- One bad recommendation can kill the program. Trust is lost instantly, and one signal sets the rollout back.
- Data was never the shortage. Companies already have access to several dashboards; value shows up only when reps act on a signal.
A WATCH-OUT FOR ALL OF US
What if you migrate everything, and nothing changes?
I think you can never really look at it as a lift and shift. At the end of the day, transformation comes in different ways. - A panelist at Axtria Ignite 2026
The panel named that as the failure mode. Instead, design the sales model, engagement, and tool together, so the CRM guides the next conversation, not the last one.
The real question: How do you change how people work?
THE SHIFT
The advantage is sequencing
Compete on how you turn AI on. Lead with a frictionless win, like voice-logged calls, and hold pre-call planning back until it survives a bad recommendation. Keep the rep in the driver's seat, weighing and choosing.
THE CONVERSATION
An Axtria Ignite 2026 panel moderated by Ernie Payne of Conexus Solutions, with leaders from AstraZeneca and Immunocore.
INSIDE THE REPORT
What the roadmap leaves out
How to sell a migration nobody asked for, sequence AI so reps' first experience is a win, and keep the rep as final decision-maker.
GET THE REPORT
Read the part of the CRM reset the roadmaps skip
Download the full report for the adoption playbook and the trust mechanics in the leaders' own words. 2030 is closer than it looks.
WHO IT'S FOR
Written for Director+ Commercial and Sales Operations leaders accountable for a migration's cost and adoption numbers. Leaders managing Customer Engagement, Customer Excellence, and Commercial IT will find just as much here.
FAQs
Expiring platform contracts, a rapidly shifting vendor landscape, and the arrival of AI-powered CRM capabilities are forcing every life sciences commercial organization to develop a CRM migration strategy, whether they planned to or not.
Rather than copying existing configurations onto a new platform, life sciences organizations should treat CRM migration as a transformation opportunity: fix foundational data gaps, retire outdated processes, and be deliberate about what to change and when to avoid field disruption.
Even the most advanced AI-driven CRM platform delivers no commercial advantage if sales reps don’t see value in using it; pharma commercial operations leaders must treat CRM transformation as a behavior and adoption challenge, not just a technology implementation.
AI in CRM is enabling pharma commercial teams to move beyond basic sales force automation toward intelligent engagement recommendations, predictive analytics, and personalized HCP outreach—but realizing that value requires clean data foundations and strong rep adoption practices.
At Axtria Ignite 2026 in Princeton, leaders from AstraZeneca and Immunocore emphasized that successful CRM transformation in pharma hinges on deliberate change management and rep-centric design, not on platform selection alone.